Specify a stock or a cryptocurrency in the search bar to get a summary
Immunome Inc
IMNMImmunome, Inc., a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington. Address: 18702 N. Creek Parkway, Bothell, WA, United States, 98011
Analytics
WallStreet Target Price
32.25 USDP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures IMNM
Dividend Analytics IMNM
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History IMNM
Stock Valuation IMNM
Financials IMNM
Results | 2019 | Dynamics |